Cusabio Technology LLC

🚨 Last Chance – ELISA Kit Discounts End Today!

Time is running out! If you haven’t taken advantage of our 96T ELISA kit promotion, this is your final call.

👉 Click here to get your discount before it’s gone: bit.ly/3PMgATu

( ) transports thyroid hormones (T4/T3) and vitamin A, ensuring proper metabolic regulation, growth, and visual function. When misfolded, TTR forms amyloid aggregates, the main pathological feature of hereditary transthyretin ( ), leading to nerve and organ damage.

provides high-quality, application-validated TTR reagents, supported by expert technical service.

👉 Discover our full TTR reagent portfolio: bit.ly/4ivP0WW

As diabetes rates rise, GCGR (Glucagon Receptor) is gaining attention for its role in regulating blood glucose. Drugs targeting GCGR, developed by Novo Nordisk and Eli Lilly, are already on the market. The combination of GCGR with multi-target receptor agonists is emerging as a promising new approach. With more companies entering the space, the GCGR market is set for disruption. Today, let's learn more about GCGR. bit.ly/4iUkKoF

GCGR: A Regulator of Energy Balance Holds a Potential in Treatment Diabetes - Cusabio With the increase in the number of diagnosed diabetes, the diabetes drugs market is estimated to grow year by year. The new drugs design over diabetes treatment has soaked up more ink and excited more passion in recent years. GCGR, as a key molecule for regulating blood glucose l

A recent study reveals how Neurotensin (NTS) regulates food intake by controlling lipid metabolism in white adipocytes. Depleting NTSR2 in adipocytes increased food intake, while NTS treatment suppressed it. The mechanism involves ceramide synthetase 2, which increases ceramides C20–C24, raising food intake and lowering GDF15 levels. The study also found a correlation between ceramide levels and food intake across different populations. These findings highlight the role of NTS-NTSR2 signaling and ceramides in appetite regulation.

Learn more: https://www.nature.com/articles/s41422-024-01038-8

🚨 Final 7 Days – ELISA Kit Discounts Ending Soon!

Don’t miss out — CUSABIO 96T ELISA kit promotion is ending in just 7 days! Take your research further — for less.

👉 bit.ly/3PMgATu

🦠 March 24 | World Tuberculosis Day

World TB Day commemorates the 1882 discovery of Mycobacterium tuberculosis by Robert Koch. TB, primarily transmitted through airborne droplets, most commonly affects the lungs.

CUSABIO provides high-quality research reagents, supporting studies targeting both MTB and host pathways. 👉 bit.ly/43WRtW2

Down Syndrome (DS), or trisomy 21, is a common chromosomal condition linked to developmental delays, intellectual disabilities, and various health challenges. While DS was misunderstood for centuries, modern research has revealed its distinct nature, separate from thyroid dysfunction.
🔬 Explore DS research related advancements: bit.ly/41ypARv

DYRK1A regulates essential processes like the cell cycle, proliferation, differentiation, and apoptosis. By modulating phosphorylation in various signaling pathways, it influences cellular stability and activity. Abnormal expression or mutations of DYRK1A are linked to diseases like Down syndrome, neurodegenerative disorders, and cancer.

CUSABIO offers high-quality DYRK1A reagents validated for multiple applications, supported by strict quality control and expert technical assistance. bit.ly/4kWzXHw

📢 𝐇𝐚𝐩𝐩𝐞𝐧𝐢𝐧𝐠 𝐓𝐨𝐝𝐚𝐲 – 𝐌𝐚𝐬𝐭𝐞𝐫𝐢𝐧𝐠 𝐄𝐋𝐈𝐒𝐀 𝐓𝐞𝐜𝐡𝐧𝐢𝐪𝐮𝐞𝐬: 𝐏𝐫𝐢𝐧𝐜𝐢𝐩𝐥𝐞𝐬, 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐂𝐮𝐫𝐯𝐞 𝐃𝐫𝐚𝐰𝐢𝐧𝐠 & 𝐃𝐚𝐭𝐚 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

To accommodate our global audience, we’re hosting three sessions—pick the time that works best for you:
🕘 𝐌𝐚𝐫𝐜𝐡 𝟏𝟗
🔹 𝟑:𝟎𝟎 𝐏𝐌 𝐉𝐒𝐓/𝐊𝐒𝐓
🔹 𝟐:𝟎𝟎 𝐏𝐌 𝐂𝐄𝐓
🔹 𝟏𝟏:𝟎𝟎 𝐀𝐌 𝐏𝐃𝐓 / 𝟐:𝟎𝟎 𝐏𝐌 𝐄𝐃𝐓

🎁 𝐁𝐨𝐧𝐮𝐬: 𝐀𝐥𝐥 𝐚𝐭𝐭𝐞𝐧𝐝𝐞𝐞𝐬 𝐡𝐚𝐯𝐞 𝐚 𝐜𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐰𝐢𝐧 𝐚 𝐅𝐑𝐄𝐄 𝟐𝟒𝐓 𝐄𝐋𝐈𝐒𝐀 𝐭𝐫𝐢𝐚𝐥 𝐤𝐢𝐭!

👉 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: bit.ly/4h5IncM

NKG2D is an activated receptor expressed on the surface of NK cells and CD8+ T cells, playing a critical role in innate immunity by recognizing virus-infected and tumor cells. This makes it a valuable target in CAR-T and CAR-NK cell therapies.
In November 2020, Nkarta Therapeutics marked a milestone with the first patient delivery of NKX101, a universal CAR-NK cell therapy targeting NKG2D for the treatment of relapsed/refractory AML and high-risk MDS. This follows earlier advancements in CAR-T NKG2D therapies, like CYAD-01 in 2018, which reached a major milestone in the treatment of metastatic colorectal cancer and achieved complete remission in patients with r/r AML. The success of NKG2D-based therapies highlights its immense potential in revolutionizing cancer treatment. Read more: bit.ly/3FBToW7

🚨 Only 3 Days Left! 🚨 Join Us for the ELISA Techniques Webinar.

👉 bit.ly/4h5IncM

Angiotensin-converting enzyme 2 (ACE2), first identified in 2000, plays a pivotal role in regulating blood pressure and fluid balance as part of the RAAS and KKS systems. This metalloproteinase (805 amino acids) has a crucial extracellular catalytic domain, and its gene is located on the X chromosome. At CUSABIO, we provide high-quality ACE2 reagents backed by rigorous quality control, validated for multiple research applications. bit.ly/4kpyIkd